Table 6.
Anti-JCV AI categories and patient’s age and disease duration.
| Age Categories | Disease Duration Categories | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| n (%) | 18–29 | 30–39 | 40–49 | 50–59 | ≥60 | 0–5 | 6–10 | 11–15 | ≥16 |
| JCV AI ≤ 0.2 | 71 (28.6) | 82 (20.7) | 70 (18.4) | 54 (20.2) | 14 (12.4) | 151 (22.8) | 62 (19.9) | 31 (16.0) | 47 (19.8) |
| 0.2 < JCV AI ≤ 0.4 | 50 (20.2) | 69 (17.4) | 52 (13.6) | 30 (11.2) | 11 (9.7) | 110 (16.6) | 45 (14.5) | 33 (17.0) | 24 (10.1) |
| 0.4 < JCV AI ≤ 0.9 | 29 (11.7) | 55 (13.9) | 40 (10.5) | 36 (13.5) | 28 (24.8) | 83 (12.5) | 39 (12.5) | 35 (18.0) | 31 (13.1) |
| 0.9 < JCV AI ≤ 1.5 | 22 (8.9) | 33 (8.3) | 42 (11.0) | 21 (7.9) | 11 (9.7) | 59 (8.9) | 33 (10.6) | 16 (8.2) | 21 (8.9) |
| JCV AI > 1.5 | 76 (30.6) | 157 (39.6) | 177 (46.5) | 126 (47.2) | 49 (43.4) | 260 (39.2) | 132 (42.4) | 79 (40.7) | 114 (48.1) |
| KW-H | p > 0.05 | p > 0.05 | |||||||
JCV AI—anti-JCV Ab index.